Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33990
Abstract: BACKGROUND Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor β (PDGFR-β), and fibroblast growth factor receptors (FGFRs). This study explored the… read more here.
Keywords: thymic carcinoma; study; rate; previously treated ... See more keywords
Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01115-4
Abstract: Purpose Despite the established activity of regorafenib in metastatic colorectal cancer (CRC), gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma (HCC), its toxicity profile has limited clinical use. We aimed to evaluate the pharmacokinetics of regorafenib… read more here.
Keywords: real world; treatment; regorafenib; oral multikinase ... See more keywords
Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical colorectal cancer"
DOI: 10.1016/j.clcc.2019.04.003
Abstract: BACKGROUND Current guidelines of the National Comprehensive Cancer Network and the European Society of Medical Oncology recommend regorafenib or trifluridine/tipiracil (TAS-102) for third-line therapy of metastatic colorectal cancer (mCRC). We evaluated the impact of regorafenib… read more here.
Keywords: muscle; tas 102; cancer; skeletal muscle ... See more keywords
Evolving role of regorafenib for the treatment of advanced cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2020.101993
Abstract: Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of refractory metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST) previously treated with imatinib and sunitinib, and unresectable hepatocellular carcinoma (HCC) following… read more here.
Keywords: placebo controlled; treatment; controlled phase; randomized placebo ... See more keywords
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2016.12.004
Abstract: Systemic chemotherapeutic treatment for unresectable and/or aggressive meningiomas is still unsatisfying. PDGF receptor (PDGFR)-mediated activation of mitogenic signalling has been shown to be active in meningiomas. Therefore, we evaluate in vitro and in vivo the effects of… read more here.
Keywords: inhibition; sorafenib; sorafenib regorafenib; meningioma ... See more keywords
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.12.001
Abstract: BACKGROUND Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib.… read more here.
Keywords: non adipocytic; activity safety; versus; placebo ... See more keywords
Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting123
Sign Up to like & getrecommendations! Published in 2019 at "Translational Oncology"
DOI: 10.1016/j.tranon.2018.12.003
Abstract: BACKGROUND: To evaluate the efficacy and toxicities of regorafenib plus irinotecan, dose-escalated on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping, in previously heavily treated metastatic colorectal cancer (mCRC) and the prognostic values of… read more here.
Keywords: metastatic colorectal; colorectal cancer; egfr expression; regorafenib folfiri ... See more keywords
PP94 Clinical Effectiveness Of Regorafenib For Metastatic Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462319002320
Abstract: Introduction Colorectal cancer (CRC) is the third most common malignant neoplasm among men and the second most common among women. According to the World Cancer Report, the number of people suffering from this disease is… read more here.
Keywords: metastatic crc; treatment; colorectal cancer; regorafenib ... See more keywords
Relapsed glioblastomas respond to regorafenib
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0161-5
Abstract: Data from a phase II trial involving patients with relapsed glioblastoma following chemoradiotherapy, a setting in which few evidence-based therapies are currently available, demonstrate the superiority of the anti-angiogenic tyrosine-kinase inhibitor regorafenib over lomustine chemotherapy.… read more here.
Keywords: glioblastomas respond; relapsed glioblastomas; oncology; regorafenib ... See more keywords
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Sign Up to like & getrecommendations! Published in 2024 at "Nature Medicine"
DOI: 10.1038/s41591-024-02824-y
Abstract: Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm,… read more here.
Keywords: phase renobate; unresectable hepatocellular; hepatocellular carcinoma; regorafenib ... See more keywords
Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-19899-3
Abstract: Glioblastoma, IDH-wildtype is the most aggressive primary brain tumor in adults, and treatment options for recurrent disease are limited. Regorafenib, an oral multikinase inhibitor, has shown efficacy in glioblastoma at first recurrence, but its role… read more here.
Keywords: oncology; diffuse gliomas; adult type; regorafenib ... See more keywords